List of Studies ( Metabolite:3-Deoxyvitamin D3)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST003817 | AN006275 | Irisin promotes bone tissue repair and intestinal protection in osteoporotic mice | Feces | Mouse | Osteoporosis | Huizhou Central People's Hospital | LC-MS |
| ST003565 | AN005857 | Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003179 | AN005221 | Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003144 | AN005159 | On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002792 | AN004542 | Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002576 | AN005612 | Role of environmental toxicants in obesity-related cardiovascular disease: Plasma untargeted LC-HRMS analysis (part 1 of 3) | Blood | Human | Heart disease | Boston University | LC-MS |
| ST002412 | AN003931 | Metabolic effects of the protein kinase R | Macrophages | Mouse | Hudson Institute of Medical Research | LC-MS | |
| ST002309 | AN003771 | Targeting malaria parasites with novel derivatives of azithromycin | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002094 | AN003421 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | LC-MS |
| ST001796 | AN002917 | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib | Mesenteric lymph | Mouse | Diabetes | Monash Institute of Pharmaceutical Sciences | LC-MS |
| ST001680 | AN002740 | Metabolome of NAFLD in high fat diet mouse model | Liver | Mouse | Fatty liver disease | Weill Cornell Medicine | LC-MS |
| ST001547 | AN002576 | β-Adrenergic regulation of metabolism in macrophages | Macrophages | Human | Monash University | LC-MS | |
| ST001315 | AN002189 | Retargeting azithromycin-like compounds as antimalarials with dual modality | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001304 | AN002172 | Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii | Fibroblast cells | Toxoplasma gondii | Parasitic infection | Monash University | LC-MS |
| ST001276 | AN002117 | Development and Characterisation of a Novel Class of Aroyl Guanidine Containing Anti-Trypanosomal Compounds | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | LC-MS |
| ST001275 | AN002116 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-II) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | LC-MS |
| ST001274 | AN002115 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | LC-MS |
| ST001205 | AN002006 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001205 | AN002006 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001204 | AN002004 | Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001204 | AN002004 | Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001202 | AN002000 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001202 | AN002000 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001201 | AN001998 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001201 | AN001998 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001175 | AN001950 | Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001033 | AN001694 | Determination of mode of action of anti-malalrial drugs using untargeted metabolomics | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000546 | AN000832 | Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium | Cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000539 | AN000818 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) | Cells | Human | Monash University | LC-MS | |
| ST000414 | AN000655 | Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action | Cells | Plasmodium falciparum | Malaria | Monash Institute of Pharmaceutical Sciences | LC-MS |
| ST000403 | AN000642 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes | Cells | Human | Monash Institute of Pharmaceutical Sciences | LC-MS | |
| ST000311 | AN000495 | TC and B6 untreated plasma in lupus-prone mice | Blood | Mouse | Lupus | University of Florida | LC-MS |
| ST000311 | AN000497 | TC and B6 untreated plasma in lupus-prone mice | Blood | Mouse | Lupus | University of Florida | LC-MS |
| ST000310 | AN000490 | TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) | Blood | Mouse | Lupus | University of Florida | LC-MS |
| ST000310 | AN000492 | TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) | Blood | Mouse | Lupus | University of Florida | LC-MS |
| ST000047 | AN000080 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000046 | AN000076 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000046 | AN000077 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | LC-MS |
